News | June 03, 2022
Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Subscribe To Our Newsletter & Stay Updated